Filana Therapeutics expects simufilam Phase 2a patient screening in TSC-related epilepsy to begin by Q1 2027

Filana Therapeutics expects patient screening in the Phase 2a study of simufilam in TSC-related epilepsy to begin by Q1 2027, following the FDA's lift of the clinical hold in September.

Detected & updated continuously · Source: Nebula